RxDoctor Payments Data

Richard Summa, MD

Pulmonary Disease · Bridgeton, MONPI 1558334227

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,174 of the $2,880 with a category attached, or 75.5%. 3 manufacturers reported payments, led by Pfizer at 58.4% of the total. Reporting peaked in 2019 at $2,810 and has fallen 98.7% since, to $37 in 2025.

$2,880in general payments, 2019–2025

Across 15 payments — averaging $191.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Eli Lilly$1K
  • Apria Healthcare LLC$13
$184,103in research payments, 2019–2025

Across 14 payments — averaging $13,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$163K
  • Pfizer$21K

What the payments were for

  • Travel & lodging$2,17475%
  • Food & beverage$70625%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer8$1,682
Eli Lilly6$1,185
Apria Healthcare LLC1$13

How this compares

$2,880 in reported general payments places this provider in the 55th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$27,076
Medicare patients
199
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter390$397,340
Dupixent PenDupilumab48$189,025
Breo ElliptaFluticasone/Vilanterol131$86,781
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$71,303
SymbicortBudesonide/Formoterol Fumarate94$40,747
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$38,147
Spiriva HandihalerTiotropium Bromide35$35,578
Incruse ElliptaUmeclidinium Bromide53$35,441
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate113$30,901
Arnuity ElliptaFluticasone Furoate68$30,868
Combivent RespimatIpratropium/Albuterol Sulfate25$25,941
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$24,203
Spiriva RespimatTiotropium Bromide25$20,386
ArexvyRsvpref3 Antigen/As01e/Pf72$18,316
Fluticasone-SalmeterolFluticasone Propion/Salmeterol95$16,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$1,682$4,82411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →